-
Because of the high cardiovascular risk associated with prehypertension, both lifestyle and pharmacological interventions should be vigorously utilized to prevent its progression to full-blown hypertension with its associated higher rates of both morbidity and mortality.
-
Recommended periodic preventive services are more likely to be performed through a scheduled screening physical examination or other dedicated preventive visits.
-
The FDA has approved a new oral tyrosine kinase inhibitor with potent, reversible, selective dual inhibition of epidermal growth factor receptor (EGFR) and ErbB2 kinases.
-
When compared to The Zone, Ornish, or LEARN diets, the very low carbohydrate diet (Atkins), showed that premenopausal, overweight, and obese women lost more weight and had the most beneficial metabolic effects at 12 months.
-
In a group of smokers who were hospitalized with cardiac symptoms, a combination of 12 weeks of behavior modification counseling plus pharmacotherapy resulted in higher tobacco abstinence rates, lower re-hospitalization rates, and markedly reduced mortality rates compared with usual care over two years of follow-up.
-
Two recent large studies have looked at the effects of various inhaler combinations on outcomes in patients with COPD.
-
-
That there is a link between inflammation and atherosclerosis is no longer in dispute. Whether modulation of inflammation might change the process of atherosclerosis, or even better, reduce vascular endpoints, remains a challenging question.
-
The FDA has approved aliskiren, the first of a new class of antihypertensive drugs, the oral renin inhibitors.
-
Using a large pharmacy data base, Irish investigators tracked Tamoxifen use and calculated prescription adherence. By 3.5 years after initial dose, approximately 1/3 of patients had discontinued use.